Kadcyla Better Than Herceptin for Early-Stage, HER2+ Residual BC
Kadcyla Seems Better Than Herceptin for Early-Stage, HER2-Positive Residual Breast Cancer
December 13, 2018
The KATHERINE trial suggests that Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) improves disease-free survival compared to Herceptin (chemical name: trastuzumab) in people diagnosed with early-stage, HER2-positive disease who have cancer cells found in tissue removed during surgery after chemotherapy that includes a taxane and Herceptin or Herceptin and Perjeta (chemical name: pertuzumab). Read more...